Breaking Headlines

Category archive

children

BREAKING: Non-Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) – Global Forecast to 2021

in Baby's/BREAKING NEWS/children/fetal/Health/medical/prenatal testing market/research/Technology/Women by
Reading Time: 3 minutes

NEW YORK, April 6, 2017 /360WiseNews/ —

The global non-invasive prenatal testing (NIPT) market is projected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021.

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.

Read the full report: http://www.reportlinker.com/p04814911/Non-Invasive-Prenatal-Testing-NIPT-Market-by-Instruments-Ultrasound-NGS-PCR-Microarray-Consumables-Method-FCMB-cf-DNA-Application-Trisomy-Microdeletion-Genetics-Rh-factor-End-User-Hospital-Diagnostic-Labs-Global-Forecast-to.html

By product, the non-invasive prenatal testing market is segmented into consumables and instruments. In 2016, the consumables segment accounted for the largest share of the market. The high demand due to the recurring requirement of consumables as compared to instruments is a key driver for the growth of this product segment.

On the basis of method, the market is segmented into ultrasound detection, biochemical screening tests, fetal cells in maternal blood tests, and cell-free DNA in maternal plasma tests. The ultrasound detection segment dominated the market in 2016. However, the cell-free DNA in maternal plasma tests segment is expected to grow at the highest CAGR. This is mainly attributed to the increasing demand for cf-DNA based techniques in NIPT testing and rising government initiatives to provide prenatal services.

On the basis of application, the market is segmented into Trisomy, microdeletion syndrome, and other applications. Trisomy commands the largest and fastest-growing application segment of the global market in 2016. This is attributed to factors such as increasing maternal age and rising incidence of chromosomal abnormalities. Keep Reading

Indie Music Sensation Hello Kylie Releases New Single and Video

in BREAKING NEWS/campaign/children/Entertainment/Music/Press Release by
Reading Time: 2 minutes

11-year-old artist Hello Kylie drops new single called Feature From Quavo through the independent music label New Muzik Order.

LOS ANGELES, March 30, 2017 /360WiseNews/ — Hello Kylie is back with a new single that drops on all major streaming services, YouTube and in App Stores on March 29th. Hello Kylie is an 11-year-old artist from Los Angeles.  Her music has inspired a new generation to get out and play, make videos, and share with others online. Hello Kylie has been recording singles and making videos for years, while growing a following on musical.ly and Youtube that’s in the millions. Her latest single Feature from Quavo is being released by independent music label, New Muzik Order and is, according to them, her most mature and rounded single yet.

Kylie jumped on the music scene in 2016 when she released her 1st single “Sleep is for Suckas” (https://www.youtube.com/watch?v=MqkNvCp9VZk)  A video that featured a 10yr old Kylie visiting her grandmother in an “Old Folks” home which grew in the millions.

Kylie’s 2nd record Abracadabbra (https://www.youtube.com/watch?v=JjHB9S7vT4A) was released in Sept 2016 and had over 75 million musical.ly likes and views and over 500,000 videos were made using Hello Kylie’s song and hashtags.

Technology has brought about the rise of independent music labels and artists that might never have been seen without the help of social media platforms.  Hello Kylie’s YouTube channel has thousands of subscribers and millions of views. Working with New Muzik Order has helped the young songstress not only receive the production value in her music, but also has helped  artist  reach a wider audience. Keep Reading

GHIT Fund Invests in Late-stage Trial for Child-friendly “Snail Fever” Medicines–One of the Most Debilitating and Widespread Parasitic Diseases in Africa

in BREAKING NEWS/children/Health/medicine by
Reading Time: 7 minutes

Completion of Phase 3 trial for treatment of “Snail Fever” (aka schistosomiasis) is final step before regulatory and WHO submission; GHIT also announces new investment in novel malaria vaccine and therapeutic for dengue, continued support for innovative tools to tackle malaria and neglected tropical diseases

TOKYO, March 30, 2017 /360WiseNews/ — The Global Health Innovative Technology Fund (GHIT Fund), a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced 11 new investments totaling US$23 million* that could help deliver a range of new innovative therapies for a host of debilitating conditions.

This latest round of targeted support includes funding for a Phase 3 clinical trial testing a pediatric formulation of a drug considered the gold standard for treating schistosomiasis, a water-borne parasitic disease linked to an assortment of acute and chronic health problems. Young children are most at risk, but the existing drug is so bitter and hard to swallow that kids often go untreated, leading to serious lifelong health and learning problems.

This clinical trial is one of the most advanced partnerships invested by the GHIT Fund, an organization that combines Japan’s historic leadership in global health and innovation with groundbreaking research from across the globe. The GHIT Fund also is making new investments in two malaria vaccine candidates, while accelerating work to find new drug treatments for malaria, dengue, Chagas disease, cryptosporidiosis and leishmaniasis.

“We’re reaching an exciting phase where GHIT’s approach to partnerships and drug and vaccine development is starting to produce tangible progress towards product deployment that could eventually lead to revolutionary breakthroughs,” said BT Slingsby, MD, PhD, MPH, who is CEO of the GHIT Fund. “We knew that combining Japan’s wealth of biomedical research talent and pharmaceutical capabilities with leading infectious disease experts near and far was likely to be a winning combination, and that’s been validated by the progress we are seeing across a rich diversity of projects.”

A Snail Fever Drug That’s Easy to Swallow

Schistosomiasis, sometimes called “snail fever” because it’s found in freshwater snails, leads to both acute and chronic disease. It’s caused by parasitic worms known as blood flukes and is usually transmitted through contact with infested water. The disease is endemic in 78 developing countries and, according to the World Health Organization, more than 261 million people, including 100 million children, were infected with schistosomiasis in 2015. Some 90 percent of infections occur in Africa, where safe water is often scarce. While rarely fatal, left untreated, the disease can cause anemia, stunted growth, impaired learning ability and chronic inflammation of vital organs.

GHIT Fund’s investment of US$4.7 million, with co-funding from its partners, will support a Phase 3 clinical trial in Africa to evaluate a pediatric formulation of praziquantel (PZQ) in children aged three months to six years. Since the 1970s, the gold-standard of treatment for the disease has been a single oral dose of PZQ used to treat adults and school-aged children. But children under age five who are infected with schistosomiasis are not treated with PZQ under the current policy. And data on the treatment of these children has been sparse and insufficient to define and confirm the best dosing. In addition, the current tablets have a severe bitter taste and the large size of the existing pill makes it difficult or just impossible for small children to swallow. A smaller, more palatable pill that could be administered to children as young as three months old is being developed by the Pediatric Praziquantel Consortium, a nonprofit international public-private partnership involving Astellas Pharma Inc. (Japan), Lygature (The Netherlands), Merck KGaA (Germany), the Swiss Tropical and Public Health Institute, Simcyp Limited (UK), Farmanguinhos (Brazil) and the Schistosomiasis Control Initiative (SCI, UK). Keep Reading

Partnership for Safety of Children Around Firearms Launches Store it Safe Campaign

in BREAKING NEWS/children/firearms/Partnership/Press Release by
Reading Time: 2 minutes

COLUMBUS, Ohio, March 6, 2017 /360WiseNews/ — The Ohio Chapter, American Academy of Pediatrics (Ohio AAP) has teamed up with firearm owners, pediatricians and others to create the Partnership for Safety of Children Around Firearms, and a pilot program called Store it Safe, to encourage safe storage of firearms and educate families about safety issues.

“Twenty-five percent of Ohio counties have had gun-related accidental injuries and deaths in children under 18 since 2015,” said Melissa Wervey Arnold, CEO, Ohio Chapter, American Academy of Pediatrics. “It was clear we needed to address this growing issue and pull resources from other organizations to form this first-of-its-kind partnership.”

The Partnership has been founded on the belief that gun ownership is a personal choice. It will not engage in debating firearm owner rights. The Partnership includes the Buckeye Firearms Association, Black Wing Shooting Center, Kiwanis Club of Columbus and many other interested parties.

The goals of the Partnership are to:

  • Prevent firearm-related, unintentional deaths and suicides among children and teens
  • Change the approach in talking about firearm safety
  • Store it Safe and teach children safety around firearms

Kiwanis Club of Columbus has provided $10,000 to purchase gun lock boxes that will be handed out at 2 and 3-year-old well-visit check-ups in several Nationwide Children’s Hospital pediatric offices in central Ohio.

“We believe strongly in the second amendment, but we also believe in being a responsible gun owner and protecting our children,” said Gerard Valentino, co-founder, Buckeye Firearms Association. “This partnership is unique and we’re thrilled to be part of it and have all parties at the table to discuss gun safety.”

For more information about gun safety and Ohio AAP’s initiatives, visit: http://ohioaap.org/firearmsafety.

The Ohio Chapter of the American Academy of Pediatrics (Ohio AAP) promotes the health, safety and well-being of children and adolescents so they may reach their full potential. The Ohio AAP works to accomplish this by addressing the needs of children, their families, and their communities, and by supporting Chapter members through advocacy, education, research, service, and improving the systems through which they deliver pediatric care. For more information, visit www.ohioaap.org.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/partnership-for-safety-of-children-around-firearms-launches-store-it-safe-campaign-300418657.html

SOURCE The Ohio Chapter, American Academy of Pediatrics (Ohio AAP)

Go to Top